<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR19">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cavo</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma</article-title>
  <source>Leukemia</source>
  <year>2015</year>
  <volume>29</volume>
  <fpage>2429</fpage>
  <lpage>2431</lpage>
  <pub-id pub-id-type="doi">10.1038/leu.2015.274</pub-id>
  <?supplied-pmid 26442610?>
  <pub-id pub-id-type="pmid">26442610</pub-id>
 </element-citation>
</ref>
